Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Notes Payables: 2019-2020

  • Pharming Group N.V's Notes Payables fell 100.97% to -$496,000 in Q4 2020 from the same period last year, while for Dec 2020 it was -$496,000, marking a year-over-year decrease of 100.97%. This contributed to the annual value of -$496,000 for FY2020, which is 100.97% down from last year.
  • Per Pharming Group N.V's latest filing, its Notes Payables stood at -$496,000 for Q4 2020, which was down 100.97% from $51.1 million recorded in Q4 2019.
  • Pharming Group N.V's Notes Payables' 5-year high stood at $51.1 million during Q4 2019, with a 5-year trough of -$496,000 in Q4 2020.
  • For the 2-year period, Pharming Group N.V's Notes Payables averaged around $25.3 million, with its median value being $25.3 million (2019).
  • Data for Pharming Group N.V's Notes Payables shows a maximum YoY tumbled of 100.97% (in 2020) over the last 5 years.
  • Pharming Group N.V's Notes Payables (Quarterly) stood at $51.1 million in 2019, then tumbled by 100.97% to -$496,000 in 2020.